WASHINGTON — Economic advisers at the White House project that pharmaceutical agreements negotiated by President Donald Trump’s administration could generate $529 billion in economic benefits over the coming decade by bringing U.S. prescription medication costs in line with international pricing.
The projections, secured by The Associated Press, represent the first comprehensive economic modeling of a policy central to Trump’s electoral strategy ahead of November’s congressional races. Democratic officials remain skeptical of the administration’s savings calculations, and these latest figures are expected to prompt further scrutiny of the underlying data.
Affordability concerns dominate voter priorities, with energy costs related to the Iran conflict intensifying public financial worries. Trump has attempted to tackle these concerns by emphasizing his pharmaceutical negotiations aimed at eliminating the significant price gap between U.S. drug costs and those in other wealthy nations.
“Now you have the lowest drug prices anywhere in the world,” Trump declared during a Friday gathering of senior citizens in Florida. “And that alone should win us the midterms.”
White House Council of Economic Advisers staff conducted the economic modeling. Their calculations also suggest that federal and state Medicaid programs could collectively save $64.3 billion throughout the next ten years under Trump’s “most favored nation” pricing strategy.
Limited public disclosure of the agreements between the Trump administration and 17 major drug manufacturers makes independent verification of the projected benefits challenging. The White House study attempted to forecast savings as additional medications enter the market under Trump’s framework, with one scenario suggesting potential decade-long savings reaching $733 billion.
Trump and his Health and Human Services Department have characterized the pharmaceutical agreements as groundbreaking and pushed Congress to enshrine their principles in legislation. Democratic legislators have disputed the administration’s benefit claims. Senate Finance Committee Ranking Member Ron Wyden of Oregon, along with 17 Democratic Senate colleagues, introduced an April proposal demanding the administration reveal the terms of pharmaceutical company agreements.
“If these deals are so great, why is the Trump administration afraid of showing them to the public?” Wyden questioned when unveiling the proposal. Health Secretary Robert F. Kennedy Jr. indicated his department would provide details excluding proprietary data or trade secrets.
The Trump administration’s estimated benefits would represent significant savings given that Americans purchased $467 billion worth of prescription medications in 2024, based on the latest available federal statistics. The analysis assumes foreign nations would increase their prescription drug payments, diversifying pharmaceutical revenue streams while maintaining companies’ research and development capabilities.
The Congressional Budget Office projected in October 2024 that a comparable plan to Trump’s eventual approach might lower prescription drug costs by over 5%, though the reduction “would probably diminish over time as manufacturers adjusted to the new policy by altering prices or distribution of drugs in other countries.”
The magnitude of the Trump administration’s claimed savings will likely increase Democratic oversight, as they argue that any price reductions would be neutralized by higher costs for medications outside the “most favored nation” structure. A primary Democratic criticism centers on pharmaceutical companies increasing profit margins while participating in the administration’s program.
Staff members working with Senator Bernie Sanders of Vermont published an April analysis examining 15 companies participating in the drug pricing initiative, discovering their collective profits surged 66% in the previous year to $177 billion. The study highlighted that Trump’s tax legislation from last year “exempted or delayed many of the most expensive drugs” from Medicare price negotiations.
The Trump administration has dismissed Sanders’ analysis as fundamentally flawed, arguing it relies on pharmaceutical list prices rather than the actual costs patients pay.
